Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119671) titled 'Efficacy and Safety of Camrelizumab plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma with Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study' on March 2.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Xiangya Hospital Central South University

Condition: Hepatocellular Carcinoma

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-03-02

Target Sample Size: Camrelizumab plus Rivoceranib and Local Therapy:32;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=...